Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GEMP Gemphire Therapeutics (GEMP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Gemphire Therapeutics Stock (NASDAQ:GEMP) 30 days 90 days 365 days Advanced Chart Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Gemphire Therapeutics alerts:Sign Up Key Stats Today's Range$2.35▼$2.4550-Day Range$0.30▼$6.3852-Week Range$0.24▼$1.49Volume26,240 shsAverage Volume127,174 shsMarket Capitalization$35.25 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Read More… Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Receive GEMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gemphire Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GEMP Stock News HeadlinesHypertriglyceridemia Treatment Market Detect New Industry Opportumities 2023-2030May 11, 2023 | marketwatch.comNonalcoholic Steatohepatitis (NASH) Market 2023: Share and Growth Opportunities Forecast till 2030April 28, 2023 | marketwatch.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 24, 2024 | WealthPress (Ad)2023-2031 Non-Alcoholic Steatohepatitis Market: Latest UpdatesApril 12, 2023 | marketwatch.com2023-2031 Non-Alcoholic Steatohepatitis Market: Latest UpdatesApril 12, 2023 | marketwatch.comNonalcoholic Steatohepatitis (NASH) Market Growth and Industry Insights till 2027March 29, 2023 | marketwatch.comGlobal Hypercholesterolemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By VMReportsMarch 26, 2023 | marketwatch.com2023 Hypertriglyceridemia Treatment Market Size, Growth | Global Industry Trends [2029]March 24, 2023 | marketwatch.comSee More Headlines GEMP Stock Analysis - Frequently Asked Questions How were Gemphire Therapeutics' earnings last quarter? Gemphire Therapeutics Inc (NASDAQ:GEMP) released its earnings results on Friday, March, 15th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.15. When did Gemphire Therapeutics IPO? Gemphire Therapeutics (GEMP) raised $30 million in an initial public offering (IPO) on Friday, August 5th 2016. The company issued 3,000,000 shares at a price of $10.00 per share. Jefferies and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers. What other stocks do shareholders of Gemphire Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gemphire Therapeutics investors own include TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Pixelworks (PXLW), Clearside Biomedical (CLSD), Protalix BioTherapeutics (PLX), SCYNEXIS (SCYX) and Melinta Therapeutics (MLNT). Company Calendar Last Earnings3/15/2019Today11/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:GEMP CUSIPN/A CIK1638287 Webwww.gemphire.com Phone734-245-1700FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-419.70% Return on Assets-173.05% Debt Debt-to-Equity RatioN/A Current Ratio0.67 Quick Ratio0.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book4.39Miscellaneous Outstanding Shares14,872,000Free FloatN/AMarket Cap$35.25 million OptionableNot Optionable Beta2.82 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report This page (NASDAQ:GEMP) was last updated on 11/24/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored#1 Crypto of 2024Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemphire Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemphire Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.